Replacing Repaglinide for a Patient with Hypoglycemia on Multiple Diabetes Medications

Current Medication Regimen and Effects

The American Diabetes Association recommends metformin, a biguanide, which improves insulin sensitivity and reduces hepatic glucose production, as part of a comprehensive diabetes regimen 1
Sitagliptin, a DPP-4 inhibitor, enhances insulin secretion and inhibits glucagon secretion in a glucose-dependent manner, and is recognized for its role in comprehensive glycemic control 1, 2
Empagliflozin, an SGLT2 inhibitor, reduces glucose reabsorption in the kidneys, contributing to the comprehensive coverage of multiple pathophysiological mechanisms in type 2 diabetes 1, 2
Repaglinide, a meglitinide, stimulates insulin secretion primarily targeting postprandial glucose, but its use is associated with a risk of hypoglycemia 3, 4

Discontinuing repaglinide without replacement may be sufficient to resolve hypoglycemia while maintaining adequate glycemic control, given the patient's current regimen of metformin, sitagliptin, and empagliflozin 1, 2, 4
The combination of metformin, a DPP-4 inhibitor, and an SGLT2 inhibitor is recognized as an effective triple therapy regimen for comprehensive glycemic control 1
GLP-1 receptor agonists provide significant A1C lowering and have weight-lowering effects, working in a glucose-dependent manner to minimize hypoglycemia risk 1, 2

Adjusting meal timing or insulin regimen, such as considering a small dose of rapid-acting insulin before meals, can be an approach for postprandial control 1
For patients with renal impairment, repaglinide can be used but dose adjustments may be needed, and renal function should be considered when selecting alternative agents 6
The American College of Clinical Endocrinologists suggests considering the patient's specific postprandial hyperglycemia concerns and adjusting the timing of current medications or focusing on dietary modifications 1, 3